Acute myocardial infarction and drug-eluting stents: A green light for their use or time for measured restraint?

American Heart Journal

Volumn 153, Issue 5, 2007, Pages 719-721

  Bavry, Anthony A ^a   Bhatt, Deepak L ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOPIDOGREL;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; CATHETERIZATION; COMORBIDITY; DIABETES MELLITUS; DRUG ELUTING STENT; DRUG WITHDRAWAL; EDITORIAL; FOLLOW UP; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE REVASCULARIZATION; HUMAN; KIDNEY FAILURE; MORTALITY; PRIORITY JOURNAL; RECURRENT DISEASE; RESTENOSIS; ST SEGMENT ELEVATION; SURGICAL TECHNIQUE; THROMBOSIS; UNITED STATES;

CORONARY RESTENOSIS; DRUG DELIVERY SYSTEMS; DRUG EVALUATION; HUMANS; MYOCARDIAL INFARCTION; MYOCARDIAL REVASCULARIZATION; STENTS; TREATMENT OUTCOME;

EID: 34247256856     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2007.02.017     Document Type: Editorial

References (22)

1. Babapulle M.N., Joseph L., Belisle P., et al. A hierarchical Bayesian meta-analysis of randomised clinical trials of drug-eluting stents. Lancet 364 (2004) 583-591
2. Chen M.S., John J.M., Chew D.P., et al. Bare metal stent restenosis is not a benign clinical entity. Am Heart J 151 (2006) 1260-1264
3. Nayak A.K., Kawamura A., Nesto R.W., et al. Myocardial infarction as a presentation of clinical in-stent restenosis. Circulation 70 (2006) 1026-1029
4. Assali A.R., Moustapha A., Sdringola S., et al. Acute coronary syndrome may occur with in-stent restenosis and is associated with adverse outcomes (the PRESTO trial). Am J Cardiol 98 (2006) 729-733
5. Shuchman M. Trading restenosis for thrombosis? New questions about drug-eluting stents. N Engl J Med 355 (2006) 1949-1952
6. Rao S.V., Shaw R.E., Brindis R.G., et al. On- versus off-label use of drug-eluting coronary stents in clinical practice (report from the American College of Cardiology National Cardiovascular Data Registry [NCDR]). Am J Cardiol 97 (2006) 1478-1481
7. Kandzari D.E., Roe M.T., Ohman E.M., et al. Frequency, predictors, and outcomes of drug-eluting stent utilization in patients with high-risk non-ST-segment elevation acute coronary syndromes. Am J Cardiol 96 (2005) 750-755
8. Pasceri V., Patti G., Speciale G., et al. Meta-analysis of clinical trials on use of drug eluting stents for treatment of acute myocardial infarction. Am J Heart 153 (2007) 749-754
9. Bavry A.A., Kumbhani D.J., Helton T.J., et al. Late thrombosis of drug-eluting stents: a meta-analysis of randomized clinical trials. Am J Med 119 (2006) 1056-1061
10. Moreno R., Fernandez C., Hernandez R., et al. Drug-eluting stent thrombosis: results from a pooled analysis including 10 randomized studies. J Am Coll Cardiol 45 (2005) 954-959
11. Bavry A.A., Kumbhani D.J., Helton T.J., et al. What is the risk of stent thrombosis associated with the use of paclitaxel-eluting stents for percutaneous coronary intervention? a meta-analysis. J Am Coll Cardiol 45 (2005) 941-946
12. Bavry A.A., Kumbhani D.J., Helton T.J., et al. Risk of thrombosis with the use of sirolimus-eluting stents for percutaneous coronary intervention (from registry and clinical trial data). Am J Cardiol 95 (2005) 1469-1472
13. Spertus J.A., Kettelkamp R., Vance C., et al. Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry. Circulation 113 (2006) 2803-2809
14. Iakovou I., Schmidt T., Bonizzoni E., et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 293 (2005) 2126-2130
15. Newby L.K., LaPointe N.M., Chen A.Y., et al. Long-term adherence to evidence-based secondary prevention therapies in coronary artery disease. Circulation 113 (2006) 203-212
16. Eisenstein E.L., Anstrom K.J., Kong D.F., et al. Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. JAMA 297 (2007) 159-168
17. Pfisterer M., Brunner-LaRocca H.P., Buser P.T., et al. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. J Am Coll Cardiol 48 (2006) 2584-2591
18. Steinhubl S.R., Berger P.B., Mann J.T., et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 288 (2002) 2411-2420
19. Grines C.L., Bonow R.O., Casey D.E., et al. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents. J Am Coll Cardiology 49 (2007) 734-739
20. Joner M., Finn A.V., Farb A., et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol 48 (2006) 193-202
21. Libby P., and Theroux P. Pathophysiology of coronary artery disease. Circulation 111 (2005) 3481-3488
22. HORIZONS trial. Available at:. http://www.tctmd.com/csportal/appmanager/tctmd/main?_nfpb=true&_page Label=TCTMDContent&hdCon=770592 [Accessed February 7, 2007]